Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy
International Immunopharmacology · 2026-11 · 189 · 117405
DOI: 10.1016/j.intimp.2026.117405 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-11. Verfasst von Enat Mengistu Leta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 100081, Beijing, China. Electronic addr…. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Neoplasms, Immunotherapy, Antibodies, Monoclonal. Die Arbeit nennt 111 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a critical immune checkpoint receptor that restrains T-cell activation and maintains peripheral tolerance by outcompeting CD28 for shared B7 ligands on antigen-presenting cells (APC). Dysregulation of CTLA-4 signaling is implicated in autoimmune pathologies, lymphoproliferative disorders, and tumor immune evasion, underscoring its broad therapeutic relevance. As the first checkpoint target validated in cancer immunotherapy, CTLA-4 has been extensively characterized at the structural level. High-resolution crystallographic studies have revealed how its extracellular IgV-like domain, MYPPPY ligand-binding motif, and cytoplasmic trafficking machinery collectively encode inhibitory function. Therapeutic antibodies targeting CTLA-4, including the FDA-approved agents ipilimumab and tremelimumab, achieve checkpoint blockade through steric occlusion of the B7-binding interface, inhibition of transendocytosis, and Fc-mediated regulatory T-cell depletion. Despite shared mechanisms, these agents differ markedly in effector function and toxicity profile. Other antibodies, including JS007, have entered clinical evaluation, while structurally characterized agents such as mipi.4 and KN044 provide preclinical and translational insights. Emerging engineering strategies, Fc-optimized variants, tumor-activated prodrug formats, bispecific antibodies, and alternative scaffolds such as nanobodies and DARPins are now translating these structural insights into next-generation therapeutics with improved selectivity and reduced immune-related adverse events. By connecting atomic-level receptor recognition to clinical outcome, this review provides a mechanistic foundation for the rational design of next-generation CTLA-4 therapeutics with improved efficacy and reduced immune-related toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 100081, Beijing, China. Electronic address: enat.leta@bit.edu.cn.
- Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 100081, Beijing, China.
- School of Computer Science and Technology, Beijing Institute of Technology, 100081, Beijing, China.
- Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 100081, Beijing, China. Electronic address: wfeng@bit.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Leta, E. M., Syed, S., Binegde, G. N., Gu, D., Xiong, J., & Wang, F. (2026). Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy. International Immunopharmacology, 189, 117405. https://doi.org/10.1016/j.intimp.2026.117405
Vancouver
Leta EM, Syed S, Binegde GN, Gu D, Xiong J, Wang F. Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy. International Immunopharmacology. 2026;189:117405. doi:10.1016/j.intimp.2026.117405
BibTeX
@article{Leta2026,
author = {Leta, Enat Mengistu and Syed, Suaad and Binegde, Geleta Negasa and Gu, Dongjin and Xiong, Jialong and Wang, Feng},
title = {Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy},
journal = {International Immunopharmacology},
year = {2026},
volume = {189},
pages = {117405},
doi = {10.1016/j.intimp.2026.117405}
}
EUVIMED